Cure & Advancements/April 13, 2026/2 min read

First Gene Therapy for Type 1 Diabetes Moves Into Human Trials

Researchers are testing KRIYA-839, a new approach that teaches muscle cells to produce insulin. Early animal studies showed promising results that lasted years after a single treatment.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

KRIYA-839 is a gene therapy—not gene editing—that uses a harmless virus to deliver insulin-producing instructions into muscle cells
In animal studies, the treatment lowered blood sugar safely and effectively, with benefits lasting up to four years after one injection
Clinical trials in people with type 1 diabetes are planned to test whether these early results hold true in humans
This approach works by giving muscle cells a new role: making insulin and releasing it when blood sugar rises, using a built-in sensor called glucokinase

A New Way to Produce Insulin

Researchers are preparing to test a novel gene therapy called KRIYA-839 in people with type 1 diabetes. This treatment takes an innovative approach: instead of replacing damaged beta cells, it reprograms muscle cells to do the job of producing insulin.

KRIYA-839 is delivered through injections into the thigh muscle. It carries two genetic instructions: one tells cells how to make insulin, and the other provides instructions for a protein called glucokinase, which acts as a blood sugar sensor.

This is not gene editing. KRIYA-839 doesn't alter your DNA. Instead, it uses a harmless virus called an adeno-associated virus (AAV) as a delivery vehicle, much like a package carrier. This type of gene therapy is already approved to treat some rare genetic conditions.

What Early Studies Show

Before testing KRIYA-839 in humans, researchers studied it in animals with type 1 diabetes. The results were encouraging: the treatment was found to be safe and effectively lowered blood sugar levels.

In some animal studies, the blood sugar-lowering effects lasted up to four years after a single treatment. These sustained results suggest the approach may offer long-lasting benefits, though it's important to note that animal studies don't always predict human outcomes.

How the Treatment Works

Glucokinase, one of the two genes delivered by KRIYA-839, functions as an intelligent sensor. When blood sugar is low, it remains mostly inactive. When blood sugar rises, it activates and triggers muscle cells to release the insulin they've been instructed to produce.

This design mimics how the body naturally regulates blood sugar, creating a more automatic response to changing glucose levels rather than requiring external intervention.

What Comes Next

This year, researchers plan to launch clinical trials testing KRIYA-839's safety and effectiveness in people living with type 1 diabetes. These human studies will determine whether the promising results seen in animals translate to real-world benefits.

While early data is encouraging, it's important to remember that clinical trials are designed to carefully evaluate both benefits and risks. Results from these trials will help clarify what role KRIYA-839 might play in type 1 diabetes treatment.

Evidence label

Origin: diabetes.org.uk (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.